Loading clinical trials...
Loading clinical trials...
A Phase II, Open-Label Clinical Efficacy Study Defining Genomic Signatures That Correlate With Midostaurin Response in Relapsed or Refractory Acute Myeloid Leukemia (AML)
Conditions
Interventions
Midostaurin
Cytarabine
Locations
1
United States
University of Florida
Gainesville, Florida, United States
Start Date
November 1, 2018
Primary Completion Date
January 1, 2021
Completion Date
January 1, 2022
Last Updated
October 22, 2018
NCT06285890
NCT06220162
NCT04065399
NCT04628026
NCT06994676
NCT06484062
Lead Sponsor
University of Florida
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions